Comparison between plasma mycophenolic acid concentrations determined by liquid chromatography-tandem mass spectrometry and particle-enhanced turbidimetric inhibition immunoassay methods
Not Applicable
- Conditions
- lung transplantation
- Registration Number
- JPRN-UMIN000018615
- Lead Sponsor
- Department of pharmaceutical sciences, Tohoku university hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
No
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The equivalency of plasma mycophenolic acid concentration
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie mycophenolic acid's inhibition of inosine monophosphate dehydrogenase (IMPDH) in lung transplant patients?
How do LC-MS/MS and PETINIA methods impact therapeutic drug monitoring (TDM) of mycophenolic acid in lung transplant recipients?
Which biomarkers correlate with mycophenolic acid efficacy or toxicity in lung transplantation?
What adverse events are associated with mycophenolic acid in lung transplant patients and how are they managed?
How do LC-MS/MS and PETINIA methods compare in measuring immunosuppressant combinations post-lung transplant?